Industry Research Reports

Home > Reports > Medical Devices & Consumables > Global Radioligand Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Radioligand Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Industry: Medical Devices & Consumables

Published Date: 2025-11-02

Pages: 80 Pages

Report ld: 5350856

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Radioligand Therapy market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

The North America Radioligand Therapy market size was US$ million in 2024, while Europe was US$ million. The proportion of the North America was % in 2024, while Europe percentage was %, and it is predicted that Europe share will reach % in 2031, trailing a CAGR of % through the analysis period.

The global key players of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG, Curium Pharma, Precirix, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.

In North America, in terms of revenue, in 2024, the top three players hold a share about %, while in Europe, top three players hold a share nearly %.

The global Radioligand Therapy market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.

MARKET SEGMENTATION

By Company

Novartis
Advanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Actinium 225 (Ac-225)
Lutetium 177 (Lu-177)
Gallium 68 (Ga-68)
Fluorine 18 (F-18)
Other Radionuclides

Segment by Application

Neuroendocrine Neoplasms
Prostate Cancer

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).

Chapter 2: Quantitative analysis of Radioligand Therapy market size and growth potential at global, regional, and country levels.

Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).

Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Lutetium 177 (Lu-177) in China).

Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Prostate Cancer in India).

Chapter 6: Regional revenue breakdown by company, type, application and customer.

Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.

Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 9: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Radioligand Therapy value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031

1.2.2 Actinium 225 (Ac-225)

1.2.3 Lutetium 177 (Lu-177)

1.2.4 Gallium 68 (Ga-68)

1.2.5 Fluorine 18 (F-18)

1.2.6 Other Radionuclides

1.3 Market by Application

1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031

1.3.2 Neuroendocrine Neoplasms

1.3.3 Prostate Cancer

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Radioligand Therapy Market Perspective (2020-2031)

2.2 Global Market Size by Region: 2020 VS 2024 VS 2031

2.3 Global Radioligand Therapy Revenue Market Share by Region (2020-2025)

2.4 Global Radioligand Therapy Revenue Forecast by Region (2026-2031)

2.5 Major Region and Emerging Market Analysis

2.5.1 North America Radioligand Therapy Market Size and Prospective (2020-2031)

2.5.2 Europe Radioligand Therapy Market Size and Prospective (2020-2031)

2.5.3 Asia-Pacific Radioligand Therapy Market Size and Prospective (2020-2031)

2.5.4 Latin America Radioligand Therapy Market Size and Prospective (2020-2031)

2.5.5 Middle East & Africa Radioligand Therapy Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

3.1 Global Radioligand Therapy Historic Market Size by Type (2020-2025)

3.2 Global Radioligand Therapy Forecasted Market Size by Type (2026-2031)

3.3 Different Types Radioligand Therapy Representative Players

4 Breakdown Data by Application

4.1 Global Radioligand Therapy Historic Market Size by Application (2020-2025)

4.2 Global Radioligand Therapy Forecasted Market Size by Application (2026-2031)

4.3 New Sources of Growth in Radioligand Therapy Application

5 Competition Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Radioligand Therapy Players by Revenue (2020-2025)

5.1.2 Global Radioligand Therapy Revenue Market Share by Players (2020-2025)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Radioligand Therapy Revenue

5.4 Global Radioligand Therapy Market Concentration Analysis

5.4.1 Global Radioligand Therapy Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Radioligand Therapy Revenue in 2024

5.5 Global Key Players of Radioligand Therapy Head office and Area Served

5.6 Global Key Players of Radioligand Therapy, Product and Application

5.7 Global Key Players of Radioligand Therapy, Date of Enter into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments and Downstream

6.1.1 North America Radioligand Therapy Revenue by Company (2020-2025)

6.1.2 North America Market Size by Type

6.1.2.1 North America Radioligand Therapy Market Size by Type (2020-2025)

6.1.2.2 North America Radioligand Therapy Market Share by Type (2020-2025)

6.1.3 North America Market Size by Application

6.1.3.1 North America Radioligand Therapy Market Size by Application (2020-2025)

6.1.3.2 North America Radioligand Therapy Market Share by Application (2020-2025)

6.1.4 North America Market Trend and Opportunities

6.2 Europe Market: Players, Segments and Downstream

6.2.1 Europe Radioligand Therapy Revenue by Company (2020-2025)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Radioligand Therapy Market Size by Type (2020-2025)

6.2.2.2 Europe Radioligand Therapy Market Share by Type (2020-2025)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Radioligand Therapy Market Size by Application (2020-2025)

6.2.3.2 Europe Radioligand Therapy Market Share by Application (2020-2025)

6.2.4 Europe Market Trend and Opportunities

6.3 Asia-Pacific Market: Players, Segments and Downstream

6.3.1 Asia-Pacific Radioligand Therapy Revenue by Company (2020-2025)

6.3.2 Asia-Pacific Market Size by Type

6.3.2.1 Asia-Pacific Radioligand Therapy Market Size by Type (2020-2025)

6.3.2.2 Asia-Pacific Radioligand Therapy Market Share by Type (2020-2025)

6.3.3 Asia-Pacific Market Size by Application

6.3.3.1 Asia-Pacific Radioligand Therapy Market Size by Application (2020-2025)

6.3.3.2 Asia-Pacific Radioligand Therapy Market Share by Application (2020-2025)

6.3.4 Asia-Pacific Market Trend and Opportunities

6.4 Latin America Market: Players, Segments and Downstream

6.4.1 Latin America Radioligand Therapy Revenue by Company (2020-2025)

6.4.2 Latin America Market Size by Type

6.4.2.1 Latin America Radioligand Therapy Market Size by Type (2020-2025)

6.4.2.2 Latin America Radioligand Therapy Market Share by Type (2020-2025)

6.4.3 Latin America Market Size by Application

6.4.3.1 Latin America Radioligand Therapy Market Size by Application (2020-2025)

6.4.3.2 Latin America Radioligand Therapy Market Share by Application (2020-2025)

6.4.4 Latin America Market Trend and Opportunities

6.5 Middle East & Africa Market: Players, Segments and Downstream

6.5.1 Middle East & Africa Radioligand Therapy Revenue by Company (2020-2025)

6.5.2 Middle East & Africa Market Size by Type

6.5.2.1 Middle East & Africa Radioligand Therapy Market Size by Type (2020-2025)

6.5.2.2 Middle East & Africa Radioligand Therapy Market Share by Type (2020-2025)

6.5.3 Middle East & Africa Market Size by Application

6.5.3.1 Middle East & Africa Radioligand Therapy Market Size by Application (2020-2025)

6.5.3.2 Middle East & Africa Radioligand Therapy Market Share by Application (2020-2025)

6.5.4 Middle East & Africa Market Trend and Opportunities

7 Key Players Profiles

7.1 Novartis

7.1.1 Novartis Company Details

7.1.2 Novartis Business Overview

7.1.3 Novartis Radioligand Therapy Introduction

7.1.4 Novartis Revenue in Radioligand Therapy Business (2020-2025)

7.1.5 Novartis Recent Development

7.2 Advanced Accelerator Applications

7.2.1 Advanced Accelerator Applications Company Details

7.2.2 Advanced Accelerator Applications Business Overview

7.2.3 Advanced Accelerator Applications Radioligand Therapy Introduction

7.2.4 Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2020-2025)

7.2.5 Advanced Accelerator Applications Recent Development

7.3 Mercy Radiology

7.3.1 Mercy Radiology Company Details

7.3.2 Mercy Radiology Business Overview

7.3.3 Mercy Radiology Radioligand Therapy Introduction

7.3.4 Mercy Radiology Revenue in Radioligand Therapy Business (2020-2025)

7.3.5 Mercy Radiology Recent Development

7.4 POINT Biopharma Global Inc

7.4.1 POINT Biopharma Global Inc Company Details

7.4.2 POINT Biopharma Global Inc Business Overview

7.4.3 POINT Biopharma Global Inc Radioligand Therapy Introduction

7.4.4 POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2020-2025)

7.4.5 POINT Biopharma Global Inc Recent Development

7.5 Fusion Pharma

7.5.1 Fusion Pharma Company Details

7.5.2 Fusion Pharma Business Overview

7.5.3 Fusion Pharma Radioligand Therapy Introduction

7.5.4 Fusion Pharma Revenue in Radioligand Therapy Business (2020-2025)

7.5.5 Fusion Pharma Recent Development

7.6 Telix Pharmaceuticals Ltd

7.6.1 Telix Pharmaceuticals Ltd Company Details

7.6.2 Telix Pharmaceuticals Ltd Business Overview

7.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Introduction

7.6.4 Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2020-2025)

7.6.5 Telix Pharmaceuticals Ltd Recent Development

7.7 Lantheus Holdings, Inc

7.7.1 Lantheus Holdings, Inc Company Details

7.7.2 Lantheus Holdings, Inc Business Overview

7.7.3 Lantheus Holdings, Inc Radioligand Therapy Introduction

7.7.4 Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2020-2025)

7.7.5 Lantheus Holdings, Inc Recent Development

7.8 Bayer AG

7.8.1 Bayer AG Company Details

7.8.2 Bayer AG Business Overview

7.8.3 Bayer AG Radioligand Therapy Introduction

7.8.4 Bayer AG Revenue in Radioligand Therapy Business (2020-2025)

7.8.5 Bayer AG Recent Development

7.9 Curium Pharma

7.9.1 Curium Pharma Company Details

7.9.2 Curium Pharma Business Overview

7.9.3 Curium Pharma Radioligand Therapy Introduction

7.9.4 Curium Pharma Revenue in Radioligand Therapy Business (2020-2025)

7.9.5 Curium Pharma Recent Development

7.10 Precirix

7.10.1 Precirix Company Details

7.10.2 Precirix Business Overview

7.10.3 Precirix Radioligand Therapy Introduction

7.10.4 Precirix Revenue in Radioligand Therapy Business (2020-2025)

7.10.5 Precirix Recent Development

8 Radioligand Therapy Market Dynamics

8.1 Radioligand Therapy Industry Trends

8.2 Radioligand Therapy Market Drivers

8.3 Radioligand Therapy Market Challenges

8.4 Radioligand Therapy Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Radioligand Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Radioligand Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market Radioligand Therapy Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Radioligand Therapy Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global Radioligand Therapy Revenue Share by Region (2020-2025)

Table 6. Global Radioligand Therapy Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global Radioligand Therapy Revenue Share Forecast by Region (2026-2031)

Table 8. Global Radioligand Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global Radioligand Therapy Revenue Market Share by Type (2020-2025)

Table 10. Global Radioligand Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global Radioligand Therapy Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global Radioligand Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global Radioligand Therapy Revenue Market Share by Application (2020-2025)

Table 15. Global Radioligand Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global Radioligand Therapy Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in Radioligand Therapy Application

Table 18. Global Radioligand Therapy Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Radioligand Therapy Market Share by Players (2020-2025)

Table 20. Global Top Radioligand Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2024)

Table 21. Ranking of Global Top Radioligand Therapy Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Radioligand Therapy Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Radioligand Therapy, Headquarters and Area Served

Table 24. Global Key Players of Radioligand Therapy, Product and Application

Table 25. Global Key Players of Radioligand Therapy, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Radioligand Therapy Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America Radioligand Therapy Revenue Market Share by Company (2020-2025)

Table 29. North America Radioligand Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America Radioligand Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe Radioligand Therapy Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe Radioligand Therapy Revenue Market Share by Company (2020-2025)

Table 33. Europe Radioligand Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe Radioligand Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 35. Asia-Pacific Radioligand Therapy Revenue by Company (2020-2025) & (US$ Million)

Table 36. Asia-Pacific Radioligand Therapy Revenue Market Share by Company (2020-2025)

Table 37. Asia-Pacific Radioligand Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 38. Asia-Pacific Radioligand Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 39. Latin America Radioligand Therapy Revenue by Company (2020-2025) & (US$ Million)

Table 40. Latin America Radioligand Therapy Revenue Market Share by Company (2020-2025)

Table 41. Latin America Radioligand Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 42. Latin America Radioligand Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 43. Middle East & Africa Radioligand Therapy Revenue by Company (2020-2025) & (US$ Million)

Table 44. Middle East & Africa Radioligand Therapy Revenue Market Share by Company (2020-2025)

Table 45. Middle East & Africa Radioligand Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Radioligand Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 47. Novartis Company Details

Table 48. Novartis Business Overview

Table 49. Novartis Radioligand Therapy Product

Table 50. Novartis Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 51. Novartis Recent Development

Table 52. Advanced Accelerator Applications Company Details

Table 53. Advanced Accelerator Applications Business Overview

Table 54. Advanced Accelerator Applications Radioligand Therapy Product

Table 55. Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 56. Advanced Accelerator Applications Recent Development

Table 57. Mercy Radiology Company Details

Table 58. Mercy Radiology Business Overview

Table 59. Mercy Radiology Radioligand Therapy Product

Table 60. Mercy Radiology Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 61. Mercy Radiology Recent Development

Table 62. POINT Biopharma Global Inc Company Details

Table 63. POINT Biopharma Global Inc Business Overview

Table 64. POINT Biopharma Global Inc Radioligand Therapy Product

Table 65. POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 66. POINT Biopharma Global Inc Recent Development

Table 67. Fusion Pharma Company Details

Table 68. Fusion Pharma Business Overview

Table 69. Fusion Pharma Radioligand Therapy Product

Table 70. Fusion Pharma Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 71. Fusion Pharma Recent Development

Table 72. Telix Pharmaceuticals Ltd Company Details

Table 73. Telix Pharmaceuticals Ltd Business Overview

Table 74. Telix Pharmaceuticals Ltd Radioligand Therapy Product

Table 75. Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 76. Telix Pharmaceuticals Ltd Recent Development

Table 77. Lantheus Holdings, Inc Company Details

Table 78. Lantheus Holdings, Inc Business Overview

Table 79. Lantheus Holdings, Inc Radioligand Therapy Product

Table 80. Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 81. Lantheus Holdings, Inc Recent Development

Table 82. Bayer AG Company Details

Table 83. Bayer AG Business Overview

Table 84. Bayer AG Radioligand Therapy Product

Table 85. Bayer AG Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 86. Bayer AG Recent Development

Table 87. Curium Pharma Company Details

Table 88. Curium Pharma Business Overview

Table 89. Curium Pharma Radioligand Therapy Product

Table 90. Curium Pharma Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 91. Curium Pharma Recent Development

Table 92. Precirix Company Details

Table 93. Precirix Business Overview

Table 94. Precirix Radioligand Therapy Product

Table 95. Precirix Revenue in Radioligand Therapy Business (2020-2025) & (US$ Million)

Table 96. Precirix Recent Development

Table 97. Radioligand Therapy Market Trends

Table 98. Radioligand Therapy Market Drivers

Table 99. Radioligand Therapy Market Challenges

Table 100. Radioligand Therapy Market Restraints

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

List of Figures

Figure 1. Radioligand Therapy Product Picture

Figure 2. Global Radioligand Therapy Market Share by Type: 2024 VS 2031

Figure 3. Actinium 225 (Ac-225) Features

Figure 4. Lutetium 177 (Lu-177) Features

Figure 5. Gallium 68 (Ga-68) Features

Figure 6. Fluorine 18 (F-18) Features

Figure 7. Other Radionuclides Features

Figure 8. Global Radioligand Therapy Market Share by Application: 2024 VS 2031

Figure 9. Neuroendocrine Neoplasms

Figure 10. Prostate Cancer

Figure 11. Radioligand Therapy Report Years Considered

Figure 12. Global Radioligand Therapy Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Radioligand Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Radioligand Therapy Revenue Market Share by Region: 2020 VS 2024

Figure 15. North America Radioligand Therapy Revenue (US$ Million) Growth Rate (2020-2031)

Figure 16. Europe Radioligand Therapy Revenue (US$ Million) Growth Rate (2020-2031)

Figure 17. Asia-Pacific Radioligand Therapy Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. Latin America Radioligand Therapy Revenue (US$ Million) Growth Rate (2020-2031)

Figure 19. Middle East & Africa Radioligand Therapy Revenue (US$ Million) Growth Rate (2020-2031)

Figure 20. Global Radioligand Therapy Market Share by Players in 2024

Figure 21. Global Top Radioligand Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Radioligand Therapy Revenue in 2024

Figure 23. North America Radioligand Therapy Market Share by Type (2020-2025)

Figure 24. North America Radioligand Therapy Market Share by Application (2020-2025)

Figure 25. Europe Radioligand Therapy Market Share by Type (2020-2025)

Figure 26. Europe Radioligand Therapy Market Share by Application (2020-2025)

Figure 27. Asia-Pacific Radioligand Therapy Market Share by Type (2020-2025)

Figure 28. Asia-Pacific Radioligand Therapy Market Share by Application (2020-2025)

Figure 29. Latin America Radioligand Therapy Market Share by Type (2020-2025)

Figure 30. Latin America Radioligand Therapy Market Share by Application (2020-2025)

Figure 31. Middle East & Africa Radioligand Therapy Market Share by Type (2020-2025)

Figure 32. Middle East & Africa Radioligand Therapy Market Share by Application (2020-2025)

Figure 33. Novartis Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 34. Advanced Accelerator Applications Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 35. Mercy Radiology Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 36. POINT Biopharma Global Inc Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 37. Fusion Pharma Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 38. Telix Pharmaceuticals Ltd Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 39. Lantheus Holdings, Inc Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 40. Bayer AG Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 41. Curium Pharma Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 42. Precirix Revenue Growth Rate in Radioligand Therapy Business (2020-2025)

Figure 43. Bottom-up and Top-down Approaches for This Report

Figure 44. Data Triangulation

Figure 45. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Radioligand Therapy market? zhanKai

The top companies in the global Radioligand Therapy market are Novartis、Advanced Accelerator Applications、Mercy Radiology.

Related Reports

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Radioligand Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-06-16
Pages: 110
USD 3950.00
(Single User License)
Global Radioligand Therapy Market Research Report 2026
The global Radioligand Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-17
Pages: 103
USD 2900.00
(Single User License)
Global Radioligand Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Radioligand Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-02
Pages: 128
USD 4900.00
(Single User License)
Radioligand Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Radioligand Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 91
USD 3950.00
(Single User License)
Global Radioligand Therapy Market Research Report 2025
The global market for Radioligand Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-01
Pages: 79
USD 2900.00
(Single User License)
Global Radioligand Therapy Market Research Report 2024
The global Radioligand Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-02-06
Pages: 82
USD 2900.00
(Single User License)
Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Radioligand Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-01-11
Pages: 109
USD 3950.00
(Single User License)

Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Radioligand Therapy was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-06-16
Pages: 110
USD 3950.00 (Single User License)
Global Radioligand Therapy Market Research Report 2026
The global Radioligand Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-17
Pages: 103
USD 2900.00 (Single User License)
Global Radioligand Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Radioligand Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-02
Pages: 128
USD 4900.00 (Single User License)
Radioligand Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Radioligand Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 91
USD 3950.00 (Single User License)
Global Radioligand Therapy Market Research Report 2025
The global market for Radioligand Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-01
Pages: 79
USD 2900.00 (Single User License)
Global Radioligand Therapy Market Research Report 2024
The global Radioligand Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-02-06
Pages: 82
USD 2900.00 (Single User License)
Radioligand Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Radioligand Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published: 2024-01-11
Pages: 109
USD 3950.00 (Single User License)